Cargando…
Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old
Background and Objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving thi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028114/ https://www.ncbi.nlm.nih.gov/pubmed/35455335 http://dx.doi.org/10.3390/vaccines10040586 |
_version_ | 1784691535988654080 |
---|---|
author | Greish, Khaled Alawadhi, Abdulla Jaradat, Ahmed Almarabheh, Amer AlMadhi, Marwa Jawad, Jaleela Alsaffar, Basma Alalawi, Ejlal Alsayyad, Adel Merza, Afaf Alalawi, Batool Qayed, Donia Humaidan, Ahmed Al Qahtani, Manaf |
author_facet | Greish, Khaled Alawadhi, Abdulla Jaradat, Ahmed Almarabheh, Amer AlMadhi, Marwa Jawad, Jaleela Alsaffar, Basma Alalawi, Ejlal Alsayyad, Adel Merza, Afaf Alalawi, Batool Qayed, Donia Humaidan, Ahmed Al Qahtani, Manaf |
author_sort | Greish, Khaled |
collection | PubMed |
description | Background and Objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving this age group in the vaccination program in the kingdom of Bahrain. Subjects and Methods: The study included 582 children from 3 to 12 years old of Bahraini and non-Bahraini nationality, all of which contributed to the reactogenicity study. Of those, 401 contributed to the immunogenicity study. All children received 2 doses of BBIBP-CorV inactivated virus 3 weeks apart. To assess reactogenicity, children were followed up for 5 weeks to evaluate any vaccine-related adverse events (AE). To assess immunogenicity, blood was collected on day 0 and day 35 to assess antibody titer against S, N, and neutralizing antibody. Results: Of the 582 participants, (45.4%) were female, (54.61%) were male, with 49% in 9–12 age group. Of the 401 children contributing to the immunogenicity study, 274 (68.3%) had no prior exposure to COVID-19. The overall incidence of AE was 27.7%. No significant difference was found among different age groups. The most frequent AE was local (at the injection site) and occurred in 16% of children, followed by fever in 9.3%. No serious adverse events were reported. The Seroconversion rate was 100% among children with no prior exposure to COVID-19. Children with previous COVID-19 exposure had higher averages of anti-S (2379 U/mL compared to 409.1), anti-N (177.6 U/mL compared to 30.9) and neutralizing antibody (93.7 U/mL compared to 77.1) than children with no prior exposure at day 35. Conclusions: Two doses of COVID-19 BBIBP-CorV on the subjects aged between 3 to 12 has good safety and tolerance and can induce an effective immune response and neutralizing antibody titer. |
format | Online Article Text |
id | pubmed-9028114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90281142022-04-23 Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old Greish, Khaled Alawadhi, Abdulla Jaradat, Ahmed Almarabheh, Amer AlMadhi, Marwa Jawad, Jaleela Alsaffar, Basma Alalawi, Ejlal Alsayyad, Adel Merza, Afaf Alalawi, Batool Qayed, Donia Humaidan, Ahmed Al Qahtani, Manaf Vaccines (Basel) Article Background and Objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving this age group in the vaccination program in the kingdom of Bahrain. Subjects and Methods: The study included 582 children from 3 to 12 years old of Bahraini and non-Bahraini nationality, all of which contributed to the reactogenicity study. Of those, 401 contributed to the immunogenicity study. All children received 2 doses of BBIBP-CorV inactivated virus 3 weeks apart. To assess reactogenicity, children were followed up for 5 weeks to evaluate any vaccine-related adverse events (AE). To assess immunogenicity, blood was collected on day 0 and day 35 to assess antibody titer against S, N, and neutralizing antibody. Results: Of the 582 participants, (45.4%) were female, (54.61%) were male, with 49% in 9–12 age group. Of the 401 children contributing to the immunogenicity study, 274 (68.3%) had no prior exposure to COVID-19. The overall incidence of AE was 27.7%. No significant difference was found among different age groups. The most frequent AE was local (at the injection site) and occurred in 16% of children, followed by fever in 9.3%. No serious adverse events were reported. The Seroconversion rate was 100% among children with no prior exposure to COVID-19. Children with previous COVID-19 exposure had higher averages of anti-S (2379 U/mL compared to 409.1), anti-N (177.6 U/mL compared to 30.9) and neutralizing antibody (93.7 U/mL compared to 77.1) than children with no prior exposure at day 35. Conclusions: Two doses of COVID-19 BBIBP-CorV on the subjects aged between 3 to 12 has good safety and tolerance and can induce an effective immune response and neutralizing antibody titer. MDPI 2022-04-11 /pmc/articles/PMC9028114/ /pubmed/35455335 http://dx.doi.org/10.3390/vaccines10040586 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Greish, Khaled Alawadhi, Abdulla Jaradat, Ahmed Almarabheh, Amer AlMadhi, Marwa Jawad, Jaleela Alsaffar, Basma Alalawi, Ejlal Alsayyad, Adel Merza, Afaf Alalawi, Batool Qayed, Donia Humaidan, Ahmed Al Qahtani, Manaf Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old |
title | Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old |
title_full | Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old |
title_fullStr | Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old |
title_full_unstemmed | Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old |
title_short | Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3–12 Years Old |
title_sort | safety and immunogenicity of covid-19 bbibp-corv vaccine in children 3–12 years old |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028114/ https://www.ncbi.nlm.nih.gov/pubmed/35455335 http://dx.doi.org/10.3390/vaccines10040586 |
work_keys_str_mv | AT greishkhaled safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT alawadhiabdulla safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT jaradatahmed safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT almarabhehamer safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT almadhimarwa safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT jawadjaleela safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT alsaffarbasma safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT alalawiejlal safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT alsayyadadel safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT merzaafaf safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT alalawibatool safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT qayeddonia safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT humaidanahmed safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold AT alqahtanimanaf safetyandimmunogenicityofcovid19bbibpcorvvaccineinchildren312yearsold |